DRKS00011753已完成未知
In vivo CYP3A activity in palliative care patients
niversitätsklinikum Heidelberg, Klinik für Anäthesiologie0 个研究点目标入组 41 人开始时间: 2017年2月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 41
研究概览
简要总结
Results: Partial metabolic clearance of midazolam in palliative care patients was 31.7 ± 32.1 L/h. This was a highly significant 40% reduction (p < 0.0001) in comparison with the cytochrome P450 3A activity of healthy subjects. Conclusion: Dosing of cytochrome P450 3A substrate drugs (e.g. macrolide antibiotics, benzodiazepines, calcium channel blockers) needs to be adjusted in palliative care patients; otherwise, escalation of debilitating symptoms due to drug interactions might occur.
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Every patient admitted on the ward who is at least 18 years of age could be enrolled. Hemoglobin should be >7.5 g/dL.
排除标准
- •Exclusion criteria are the need of red blood cells transfusions on a regular basis, inability to communicate well with the investigator due to language problems or poor mental development
研究者
相似试验
招募中
不适用
Observational Study;Midazolam as CYP3A phenotyping probe to investigate the effects of lapatinib on hepatic CYP3A activity.1. cancer<br />2. drug-drug interaction<br />3. CYP3A<br />4. lapatinib.NL-OMON22273Erasmus MC-Daniel den HoedDepartment of Medical OncologyGroene Hilledijk 3013075 EA Rotterdamthe Netherlands15
已完成
4 期
CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model DrugMorbid ObesityNCT01519726St. Antonius Hospital20
招募中
不适用
Midazolam as a potential CYP3A phenotyping probe for cabazitaxel metabolism.prostate cancer - bone metastases10027476NL-OMON37899Meander Medisch Centrum15
已完成
不适用
Pharmacokinetics of the CYP3A substrate Midazolam after steady-state dosing of IMU-935.Chronic inflammatory diseasesautoimmune and chronic inflammatory diseasescastration-resistant prostate cancer1000381610036958NL-OMON51575Immunic AG16
已完成
4 期
Physiological Study of the Human CYP3A Activity (PiSA)Cytochrome P450 CYP3A Enzyme DeficiencyNCT03204578University Hospital, Basel, Switzerland12